Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer, COVID-19
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal.
Updated Pfizer-BioNTech’s COVID-19 vaccine approved by Health Canada
Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against the most recently circulating variants of the virus.
Pfizer/BioNTech Covid-19 Vaccine Adapted for KP.2 Strain Gets Canada Approval
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More.
Covid-19: Pfizer/BioNTech vaccine judged safe for use in UK
The UK has become the first country in the world to approve the Pfizer/BioNTech coronavirus vaccine, paving the way for mass vaccination. Britain's medicines regulator, the MHRA, says the jab, which offers up to 95% protection against Covid-19 illness,
Pfizer's updated COVID-19 vaccine approved, Health Canada says
Pfizer-BioNTech's updated vaccine to protect against a recently circulating variant of COVID-19 is authorized, Health Canada said on Tuesday.
Pfizer, BioNTech's Omicron-Adapted Covid-19 Vaccine Gets E.U. Marketing Recommendation
Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is one step closer to becoming available across the European Union.
Health Canada approves Pfizer's updated COVID-19 vaccine, manufacturer says
Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus.
fingerlakes1
7h
Judge tosses family’s lawsuit over son’s vaccine-related death
A federal judge has dismissed a lawsuit by a New York family who claimed the Department of Defense misled Americans into ...
Yahoo News
1d
Here’s how to get free COVID tests through the mail
The announcement comes as the administration is trying to encourage people to get the updated COVID-19 vaccines from ...
22h
Judge dismisses family lawsuit against Dept. of Defense after 24-year-old’s “vaccine-related” death
A federal judge in Washington D.C. cited the government’s “general immunity” in dismissing a lawsuit that accused the ...
4h
on MSN
NHS Covid booster jabs available within days to people born after specific year
The Covid booster jab autumn scheme is opening in just a few days with some Brits eligible and encouraged to get their ...
Business Insider
7d
CHMP Recommends Marketing Authorization For Pfizer, BioNTech's Omicron KP.2-adapted COVID-19 Vaccine
(RTTNews) - Pfizer (PFE) and BioNTech SE (BNTX) announced that the CHMP of the European Medicines Agency has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent ...
Montreal News
2d
Health Canada approves Pfizer-BioNTech’s updated COVID-19 vaccine
Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...
STAT
1d
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
Pfizer
and its partner,
BioNTech
, sued Moderna in London in September 2022, seeking to revoke two patents held by Moderna ...
1d
Pfizer’s Solid Fundamentals and Strategic Acquisitions Affirm Buy Rating Despite Oxbryta Setback
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report), retaining the price target of $36.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback